Foundation Medicine, Inc. operates as a global, patient-focused precision medicine company. It provides transformative diagnostic solutions for cancer and other diseases. The company develops genomic profiling tests that guide treatment strategies for cancer patients. It offers FoundationOne CDx, a tissue-based companion diagnostic test for solid tumors; FoundationOne Liquid CDx, a blood-based companion diagnostic test for solid tumors; and a laboratory-developed test for hematologic malignancies, sarcomas, or solid tumors. It also provides biopharma partner services. Foundation Medicine, Inc. was formerly known as Foundation Genomics, Inc. and changed its name to Foundation Medicine, Inc. in February 2010. The company was incorporated in 2009 and is based in Boston, Massachusetts, with additional locations in Morrisville, North Carolina; Penzberg, Germany; and San Diego, California. As of January 31, 2022, Foundation Medicine, Inc. operates as a subsidiary of Roche Holding AG.